Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Enlivex Therapeutics Ltd

Enlivex Adopts Bitcoin Treasury Reserve Strategy
From Enlivex Therapeutics Ltd
Via GlobeNewswire
Tickers ENLV
Enlivex Announces the Dosing of the First Patient in a Phase I Clinical Trial Evaluating Allocetra in Patients with Psoriatic Arthritis
From Enlivex Therapeutics Ltd
Via GlobeNewswire
Tickers ENLV
Enlivex Announces the Enrollment and Dosing of the First 10 Patient in the Randomized Phase II Stage of its Allocetra Trial in Patients with Moderate to Severe Knee Osteoarthritis
From Enlivex Therapeutics Ltd
Via GlobeNewswire
Tickers ENLV
Enlivex Receives Notice of Allowance for Japanese Patent Application Covering the Use of Allocetra™ in Patients with Osteoarthritis
From Enlivex Therapeutics Ltd
Via GlobeNewswire
Tickers ENLV
Enlivex Receives Authorization from the Danish Medicines Agency to Initiate the Phase II Stage of its Phase I/II Trial of Allocetra in Patients with Moderate to Severe Knee Osteoarthritis
From Enlivex Therapeutics Ltd
Via GlobeNewswire
Tickers ENLV
Enlivex Announces Positive DSMB Recommendation to Initiate the Phase II Stage of its Phase I/II Trial of Allocetra in Patients with Moderate to Severe Knee Osteoarthritis
From Enlivex Therapeutics Ltd
Via GlobeNewswire
Tickers ENLV
Enlivex Receives Regulatory Authorization For The Initiation Of A Phase I Clinical Trial To Evaluate Allocetra In Patients With Psoriatic Arthritis
From Enlivex Therapeutics Ltd
Via GlobeNewswire
Tickers ENLV
Enlivex Announces the Dosing of the First Patient in a Randomized, Placebo-Controlled Phase I/II Trial Evaluating AllocetraTM in up to 46 Patients with Thumb Osteoarthritis
From Enlivex Therapeutics Ltd
Via GlobeNewswire
Tickers ENLV
Join Enlivex Therapeutics’ Chief Executive Officer for a Live Investor Webinar and Q&A Session on June 25
From Enlivex Therapeutics Ltd
Via GlobeNewswire
Tickers ENLV
Enlivex Announces Positive Interim Data Readout from a Phase I/II Trial Evaluating Allocetra in End-Stage Knee Osteoarthritis
From Enlivex Therapeutics Ltd
Via GlobeNewswire
Tickers ENLV
Enlivex Receives Regulatory Authorization for the Initiation of a Placebo-Controlled Phase I/II Trial Evaluating Allocetra in Up To 46 Patients with Thumb Osteoarthritis
From Enlivex Therapeutics Ltd
Via GlobeNewswire
Tickers ENLV
Enlivex Therapeutics Closes up to $15 Million Registered Direct Offering
From Enlivex Therapeutics Ltd
Via GlobeNewswire
Tickers ENLV
Enlivex Therapeutics Announces up to $15 Million Registered Direct Offering
From Enlivex Therapeutics Ltd
Via GlobeNewswire
Tickers ENLV
Enlivex CEO Issues Letter to Shareholders – Perspectives on Recent Events
From Enlivex Therapeutics Ltd
Via GlobeNewswire
Tickers ENLV
Enlivex Announces Dosing of First Two Patients in its Randomized, Controlled Phase I/II Trial Evaluating Allocetra™ in Patients with Knee Osteoarthritis
From Enlivex Therapeutics Ltd
Via GlobeNewswire
Tickers ENLV
Enlivex Announces Authorization from the Danish Regulatory Agency for the Company’s Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Patients with Knee Osteoarthritis
From Enlivex Therapeutics Ltd
Via GlobeNewswire
Tickers ENLV
Enlivex to Host Webcast on April 12, 2024 at 8:30 a.m. Eastern Time to Discuss Topline Results from Its Phase II Trial Evaluating Allocetra™ In Patients with Sepsis
From Enlivex Therapeutics Ltd
Via GlobeNewswire
Tickers ENLV
Enlivex Announces Topline Results of Its Phase II Trial Evaluating Allocetra™ In Patients With Sepsis
From Enlivex Therapeutics Ltd
Via GlobeNewswire
Tickers ENLV
Enlivex Announces Issuance of New U.S. Patent Covering Allocetra Cells and Their Manufacturing Method
From Enlivex Therapeutics Ltd
Via GlobeNewswire
Tickers ENLV
Enlivex Receives IMOH Regulatory Authorization for the Initiation of a Multi-Country, Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Up To 160 Patients with Moderate to Severe Knee Osteoarthritis
From Enlivex Therapeutics Ltd
Via GlobeNewswire
Tickers ENLV
Enlivex Announces Completion of Enrollment of Its Phase II Trial Evaluating Allocetra In Patients With Sepsis
From Enlivex Therapeutics Ltd
Via GlobeNewswire
Tickers ENLV
Enlivex Announces Reprioritization Plan and Second Quarter 2023 Financial Results
From Enlivex Therapeutics Ltd
Via GlobeNewswire
Tickers ENLV
Enlivex to Present at the H.C. Wainwright 25th Annual Global Investment Conference
From Enlivex Therapeutics Ltd
Via GlobeNewswire
Tickers ENLV
Enlivex Announces Peer-Reviewed Publication in Frontiers in Immunology of Clinical Data Details Resolution of Acute Respiratory Distress Syndrome (ARDS) from two Phase I/II Trials Evaluating Allocetra in Patients with COVID-19
From Enlivex Therapeutics Ltd
Via GlobeNewswire
Tickers ENLV
Enlivex Announces Dosing of First Patient Under The Amended Protocol Of Its Phase II trial Evaluating Allocetra™ In Patients With Sepsis
From Enlivex Therapeutics Ltd
Via GlobeNewswire
Tickers ENLV
Enlivex Announces First Quarter 2023 Financial Results and Provides a Business Update
From Enlivex Therapeutics Ltd
Via GlobeNewswire
Tickers ENLV
Enlivex to Present at the 2023 Jefferies Healthcare Conference
From Enlivex Therapeutics Ltd
Via GlobeNewswire
Tickers ENLV
Enlivex Selected for an Elevator Pitch Presentation and two additional Poster Presentations at the 2023 Annual Meeting of the International Society for Cell & Gene Therapy
From Enlivex Therapeutics Ltd
Via GlobeNewswire
Tickers ENLV
Enlivex Announces Issuance of European Patent Covering the Use of Allocetra™ to Prevent Cytokine Release Syndrome (CRS) Resulting from CAR T-Cell Therapy
From Enlivex Therapeutics Ltd
Via GlobeNewswire
Tickers ENLV
Enlivex Receives Notice of Allowance for U.S. Patent Application Covering the Use of Allocetra™ in Patients Receiving CAR T-Cell Therapy
From Enlivex Therapeutics Ltd
Via GlobeNewswire
Tickers ENLV
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.